EU/3/13/1108

About

On 12 March 2013, orphan designation (EU/3/13/1108) was granted by the European Commission to Sanofi-Aventis Groupe, France, for 2-[4-methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid for the treatment of systemic sclerosis.

Key facts

Active substance
2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid
Disease / condition
Treatment of systemic sclerosis
Date of first decision
12/03/2013
Outcome
Positive
EU designation number
EU/3/13/1108

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Sanofi-Aventis Groupe
54 rue de la Boétie
75008 Paris
France
Tel. +33 153 7740 00
Fax: +33 153 7741 33
Contact

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating